Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Myeloid 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 156Lung Neoplasms 99Carcinoma, Non-Small-Cell Lung 61Extensive Stage Small Cell Lung Cancer 10Adenocarcinoma of Lung 7Parkinson Disease 4, Autosomal Dominant Lewy Body 5Carcinoma, Small Cell 5Adenocarcinoma, Bronchiolo-Alveolar 5Small Cell Lung Cancer Extensive Stage 4Drug-Related Side Effects and Adverse Reactions 4Small Cell Lung Cancer Limited Stage 3SCLC, Extensive Stage 3SCLC 3Recurrence 3Radiation Injuries 3Neoplasms 3Carcinoma, Ovarian Epithelial 3Thymoma 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2SCLC,Extensive Stage 2Ovarian Neoplasms 2Melanoma 2Limited Stage Small Cell Lung Cancer 2Kidney Neoplasms 2Extensive Small Cell Lung Cancer 2Carcinoma, Neuroendocrine 2Breast Neoplasms 2

Interventions

Carboplatin 24Pemetrexed 18Cisplatin 17Paclitaxel 14pembrolizumab 13Gemcitabine 8osimertinib 7durvalumab 6Docetaxel 6Nivolumab 5Erlotinib Hydrochloride 5130-nm albumin-bound paclitaxel 5capmatinib 3brigatinib 3anlotinib 3Gefitinib 3Drug Therapy 3vosaroxin 2volociximab 2sintilimab 2pralsetinib 2ensartinib 2atezolizumab 2aflibercept 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Etoposide × Thoracic × Clear all
NCT00926640 2018-10-19

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
EndocrineThoracic

Carcinoma, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡